Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease;Factores determinantes del inicio de tratamiento con levodopa/carbidopa/entacapona en pacientes españoles con enfermedad de Parkinson

Neurologia

Volumn 29, Issue 3, 2014, Pages 153-160

  Martinez Martin P ^a   Hernandez B ^b   Ricart, J ^b   Alegre, Vicente Bertol ^c   Lasaosa, Sonia Santos ^d   Martínez, Iñiguez Martĩnez ^d   Llerda, Jose Angel Mauri ^d   Pilar Larrode Pellicer, ^d   Valiente, Sara Sánchez ^e   Gómez, Consuelo Rios ^f   Zubirendi, María Itziar Gastón ^g   Bescos, Francisco Lacruz ^h   Hernández, Gerardo Joaquín Soriano ^h   Álvarez, José María Sánchez ⁱ   González, Manuel Menéndez ^j   Moro, Roberto Suárez ^k   Martínez, Alejandro Formica ^k   Beti, Nerea Foncea ^l   Merino, Beatriz Tijero ^m   Yarza, Jesús Alberto Bergareche ⁿ   García, Enrique Corredera ^o   González, Jose Manuel Paz ^p   Reigosa, Robustiano Pego ^p   MareyLópez, José ^q   Hachem, Youssef Sayed ^r   Palomar, Eloy Elices ^r   Depego, Esteban Taleti ^s   Miralles, Bartolomé Rossiñol ^t   Balzola, Javier Esteve ^u   Cerezo, Fernando Herrero ^v   Nadal, Jordi Batlle ^w   Darde, Jaume Burcet ^x   Olivan, Fernando Espada ^y   López, Joan Bello ^z   Rivera, Asunción ávila ^z   Serra, Francesc Valldeoriola ^aa   Classen, Serge Jaumà ^ab   Lillo, Laura Gubieras ^ac   Peraire, Ana Jaén ^ad   Rodríguez, Alain Luna ^ae   Corral, Mercè Martínez ^af   Garriga, Matilde Calopa ^ab   Cirera, Joan Massons ^ag   de la Creu Fumado, Jaume Camp ^ah   Roca, Luis Borrás ^ai   Pons, Núria Caballol ^aj   Folch, Sonia Huertas ^ak   Arilla, Sonsoles Aranceta ^al   Franco, Antonio Palasí ^am   Gabriel, César Castejón ^an   Martínez, Marta Fragoso ^ao   Sán chez, Jose Antonio Arenas ^ap   Villar, M Eugenia Villar ^aq   Alonso, Pilar Sánchez ^ar   del Real Fran cia, María ángeles ^as   Alonso, Ramón ErnestoIbáñez ^as   Frech, Fernando Alonso ^at   Duarte, Jacinto ^au   Gómez, José Balseiro ^av   Arbos, Samira Fanjul ^aw   Huete, Cristina Ruiz ^ax   Martínez, Jerónimo Almajano ^ay   Izquierdo, Antonio Yusta ^az   Sendin, Miguel Angel Conde ^ba   Soldevila, Miguel Angel Garcia ^bb   Montero, Yasmina ElBerdei ^bc   León, Julián Benito ^bd   Guede, Hari Bhathal ^be   Béjar, Paloma Alonso ^bf   Bullido, Yolanda Fernández ^bg   Aroca, Ignacio López Zuazo ^bh   Dib, Wadih Bowakim ^bi   Pascual, Antonio Ortiz ^bj   Lara, Manuel Lara ^bk   Pérez, José Miguel Velázquez ^bl   Caballero, Pedro Enrique Jiménez ^bm   Romero, Jesús Olivares ^bn   Errazquin, Francisco Pérez ^bo   Heredia, María José Gómez ^bo   Moreno, José María Ramírez ^bp   Marchante, Juan José Asencio ^bq   Garcia, Francisca Terriza ^br   García, Esther Dionisia Cancho ^bs   María, José Carlos Estevez ^bt   Caballero, Francisco Sánchez ^bu   de Casasola García, M Carmen García ^bv   Brito, Jesús Norelys Lorenzo ^bw   Muñoz, José Andrés Suárez ^bx   del Rio, Pablo Eguia ^by   Nicolás, Santiago Díaz ^bx   Muedra, Carlos Perla ^bz   Mancebo, Vicente Fernando Peset ^ca   Montesinos, José F Folgado ^cb   Morán, José Andrés Domínguez ^cc   Fayos, José Cerdà ^cd   Andrés, Pilar Taberner ^ce   De Tienda, Alejandro Ponz ^cf   Martínez, Silvia Martí ^bi   Gil, José Manuel Puentes ^cg   Martínez, Vicente Medrano ^ch   Mesia, Eduardo Kahn ^ci   Torreci llas, Juan José Soria ^ci   Sauco, María álvarez ^cj   Fleta, Francisco Gracia ^ck   more..

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Departamento médico   (Spain)

^c HU Miguel Servet   (Spain)

^d Lozano Blesa Hospital   (Spain)

^e Centro Médico de Especialidades Grande Covián   (Spain)

^f Hospital General de Barbastro   (Spain)

^g Hospital Materno Infantil Virgen Del Camino   (Spain)

^h H de Navarra   (Spain)

ⁱ H de Cabu nes   (Spain)

^j H Álvarez Buylla   (Spain)

^k H Valle Del Nalón   (Spain)

^l A Ntra Sra del Coro   (Spain)

^m H de Galdakao   (Spain)

ⁿ HOSPITAL DE CRUCES   (Spain)

^o H Bidasoa   (Spain)

^p H Clínico Santiago   (Spain)

^q H Xeral de Lugo   (Spain)

^r C Saúde O Ventorrillo   (Spain)

^s Clinica Rotger   (Spain)

^t H Mateu Orfila   (Spain)

^u C de Neu rodiagnosis   (Spain)

^v H Pius deValls   (Spain)

^w Hospital of Mataro   (Spain)

^x Hospital Santa Tecla   (Spain)

^y H El Vendrell   (Spain)

^z H Sant Jaume de Olot   (Spain)

^aa Hospital de L'Hospitalet   (Spain)

^ab H Clinic i Provincial   (Spain)

^ac HU Bellvitge   (Spain)

^ad Duran i Reynals Hospital   (Spain)

^ae PASSIR CAP Num ncia   (Spain)

^af Hospital de Palamos   (Spain)

^ag Section of Gastroenterology   (Spain)

^ah HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

^ai Hospital Universitary de Bellvitge   (Spain)

^aj ABS Manso 4 Casanovas   (Spain)

^ak CAP Rambla   (Spain)

^al HOSPITAL MÚTUA DE TERRASSA   (Spain)

^am CAP Ripollet   (Spain)

^an H G Vall d'Hebron   (Spain)

^ao CAP Chafarinas   (Spain)

^ap Brain   (Spain)

^aq Servicio de Radiología   (Spain)

^ar C Especialidades Móstoles   (Spain)

^as HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^at School of Industrial Engineering of Ciudad Real   (Spain)

^au HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^av HOSPITAL GENERAL DE SEGOVIA   (Spain)

^aw HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^ax HOSPITAL SEVERO OCHOA   (Spain)

^ay Sanatorio del Rosario   (Spain)

^az HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^ba H G Universi tario Guadalajara   (Spain)

^bb Centro de Salud Federica Montseny   (Spain)

^bc C Salud Virgen del Val   (Spain)

^bd A Central Salamanca   (Spain)

^be A Villaverde Cruce   (Spain)

^bf Centro de Especialidades Peña Prieta Hermanos Sangro   (Spain)

^bg Hospital del Tajo   (Spain)

^bh A Moratalaz   (Spain)

^bi H de Guadalajara   (Spain)

^bj UNIVERSITY OF ALICANTE   (Spain)

^bk HOSPITAL CENTRAL DE LA CRUZ ROJA   (Spain)

^bl HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^bm HOSPITAL VIRGEN DE LA SALUD   (Spain)

^bn H de Torrecárdenas   (Spain)

^bo H Virgen de la Victoria   (Spain)

^bp HOSPITAL INFANTA CRISTINA   (Spain)

^bq H Puerto Real   (Spain)

^br Hospital General de Santa María del Puerto   (Spain)

^bs Hospital Don Benito   (Spain)

^bt CPEVVA   (Spain)

^bu HLlerena   (Spain)

^bv H Rambla SL Santa Cruz de Tenerife   (Spain)

^bw HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^bx HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^by HOSPITAL GENERAL DE LANZAROTE   (Spain)

^bz HOSPITAL ARNAU DE VILANOVA   (Spain)

^ca C Salut Aldaia Antic Regne   (Spain)

^cb H G d'Ontinyent   (Spain)

^cc Servicio de Endocrinología Hospital   (Spain)

^cd HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

^ce H U Dr Peset Aleixandre   (Spain)

^cf UNIVERSITY OF VALENCIA   (Spain)

^cg H Albacete   (Spain)

^ch Hospital de Elda   (Spain)

^ci Hospital Santa M del Rosell   (Spain)

^cj H G U de Elche   (Spain)

^ck H Alicante   (Spain)

more..

Author keywords

Levodopa carbidopa entacapone; Parkinson's disease

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; ANTIPARKINSON AGENT; CARBIDOPA; CATECHOL DERIVATIVE; ENTACAPONE; LEVODOPA; NITRILE;

ADULT; AGED; ARTICLE; BODY MOVEMENT; BODY POSTURE; BRADYKINESIA; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DEXTERITY; FEMALE; GENERAL CONDITION DETERIORATION; HOEHN AND YAHR SCALE; HUMAN; IDIOPATHIC DISEASE; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL SYSTEM PARAMETERS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PARKINSON DISEASE; RETROSPECTIVE STUDY; RIGIDITY; SCHWAB AND ENGLAND SCALE; SOCIAL PSYCHOLOGY; SPAIN; TIME TO TREATMENT; TREMOR; WALKING DIFFICULTY; CLINICAL TRIAL; DRUG COMBINATION; MULTICENTER STUDY; SOCIOECONOMICS;

AGED; ANTIPARKINSON AGENTS; CARBIDOPA; CATECHOLS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITRILES; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; SPAIN;

EID: 84897462262     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2012.12.008     Document Type: Article

References (31)

1. Benito-Leon J., Bermejo-Pareja F., Rodriguez J., Molina J.A., Gabriel R., Morales J.M. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord 2003, 18:267-274.
2. Abasolo-Osinaga E., Abecia-Inchaurregui L.C., Fernandez-Diaz E., Barcenilla-Laguna A., Banares-Onraita T. The prevalence and pharmacological cost of Parkinson's disease in Spain. Rev Neurol 2006, 43:641-645.
3. Levine C.B., Fahrbach K.R., Siderowf A.D., Estok R.P., Ludensky V.M., Ross S.D. Diagnosis and treatment of Parkinson's disease: a systematic review of the literature. Evid Rep Technol Assess (Summ) 2003, 1-4.
4. Shulman J.M., De Jager P.L., Feany M.B. Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol 2011, 6:193-222.
5. Lewis S.J., Foltynie T., Blackwell A.D., Robbins T.W., Owen A.M., Barker R.A. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005, 76:343-348.
6. Lees A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 2005, 22:731-740.
7. Weiner W.J. The initial treatment of Parkinson's disease should begin with levodopa. Mov Disord 1999, 14:716-724.
8. Grosset D., Taurah L., Burn D.J., MacMahon D., Forbes A., Turner K., et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2007, 78:465-469.
9. Schapira A.H., Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal?. Ann Neurol 2006, 59:559-562.
10. Beckford-Ball J. Implications of the latest NICE Parkinson's disease guidance. Nurs Times 2006, 102:25-26.
11. Horstink M., Tolosa E., Bonuccelli U., Deuschl G., Friedman A., Kanovsky P., et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006, 13:1170-1185.
12. Miyasaki J.M., Martin W., Suchowersky O., Weiner W.J., Lang A.E. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002, 58:11-17.
13. Rascol O., Brefel-Courbon C., Payoux P., Ferreira J. The management of patients with early Parkinson's disease. Adv Neurol 2003, 91:203-211.
14. McDermott M.P., Jankovic J., Carter J., Fahn S., Gauthier S., Goetz C.G., et al. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol 1995, 52:565-570.
15. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression, and mortality. Neurology 1967, 17:427-442.
16. Fahn S., Elton R.L. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. Recent developments in Parkinson's disease 1987, 2:153-164. Macmillan Healthcare Information, Florham Park.
17. Schwab R.S., England A.C. Projection technique for evaluating surgery in Parkinson's disease. Third Symposium on Parkinson's disease 1969, 152-157. E. and. S Livingstone, Edinburgh. F.J. Gillingham, I.M.L. Donaldson (Eds.).
18. Martínez-Martín P., Forjaz M.J. Metric attributes of the UPDRS 3.0 battery. Part I: feasibility, scaling assumptions, reliability, and precision. Mov Disord 2006, 21:1182-1188.
19. Martínez-Martín P., Rodríguez-Blázquez C., Kurtis M.M., Ray Chaudhuri K. The impact of non motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011, 26:399-406. on Behalf of the NMSS Validation Group.
20. Bhat V., Weiner W.J. Parkinson's disease. Diagnosis and the initiation of therapy. Minerva Med 2005, 96:145-154.
21. Levodopa and the progression of Parkinson's disease. New Engl J Med 2004, 351:2498-2508. The Parkinson Study Group.
22. Stacy M., Galbreath A. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia. Clin Neuropharmacol 2008, 31:51-56.
23. Brooks D.J. Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat 2008, 4:39-47.
24. Stocchi F., Rascol O., Kieburtz K., Poewe W., Jankovic J., Tolosa E., et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease. The STRIDE-PD Study. Ann Neurol 2010, 68:18-27.
25. Poewe W.H., Deuschl G., Gordin A., Kultalahti E.R., Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002, 105:245-255.
26. Brooks D.J., Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003, 74:1071-1079.
27. Olanow C.W., Kieburtz K., Stern M., Watts R., Langston J.W., Guarnieri M., et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004, 61:1563-1568.
28. Nissinen H., Kuoppamaki M., Leinonen M., Schapira A.H. Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis. Eur J Neurol 2009, 16:1305-1311.
29. Weiner W.J. Early diagnosis of Parkinson's disease and initiation of treatment. Rev Neurol Dis 2008, 5:46-53. quiz 4-5.
30. Garcia-Ruiz P.J., Del Val J., Fernandez I.M., Herranz A. What factors influence motor complications in Parkinson disease?: a 10-year prospective study. Clin Neuropharmacol 2012, 35:1-5.
31. Fung V.S.C., Herawati L., Wan Y. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Mov Disord 2009, 24:25-31. Movement Disorder Society of Australia Clinical Research and Trials Group, QUEST-AP Study Group.